Skip to main content
Premium Trial:

Request an Annual Quote

SC Biosciences, Cyntellect, Cenix, Bayer, Northwestern U, Cambria

Premium

SC Biosciences to Exclusively Distribute Cyntellect's LEAP System in Japan; Equity Investment Sweetens Deal

SC Biosciences, a subsidiary of Japanese trading company Sumitomo, will exclusively distribute Cyntellect's LEAP automated cell imaging and processing system and related collaborative services in Japan, the companies said last week.

SCB has also made an equity investment in Cyntellect and has ordered several LEAP units. The companies plan to ship the first instruments to Japan beginning in early 2006.

LEAP, which stands for laser-enabled analysis and processing, combines high-speed optical imaging of cells with real-time image analysis and high-speed laser manipulation of individual live cells in microplates.

Cyntellect, based in San Diego, said it will evaluate other potential commercial partners for LEAP for further geographic areas.


Cenix Delivers Drug Targets to Bayer, Receives Milestone Payment

Cenix Bioscience announced last week that it has delivered to partner Bayer a collection of potential drug targets, which were identified using RNAi.

According to Cenix, the targets were identified as part of a December 2003 RNAi-based discovery collaboration in which cell-based assays originally developed by Bayer were adapted and optimized by Cenix to be run as high-throughput RNAi screens.

Under the terms of the collaboration, Bayer acquired the first option to secure all rights to new target-related intellectual property generated by the project. According to Cenix, Bayer has sought patent protection on the targets just delivered, triggering an undisclosed milestone payment to Cenix.


Northwestern U Wins Drug Screening Grant from ALS Association; Cambria to Collaborate

The ALS Association last week announced funding for a project headed by Northwestern University researcher Richard Morimoto to screen for new amyotrophic lateral sclerosis therapies.

The project will screen for compounds that interact with mutant forms of an ALS-associated protein in Caenorhabditis elegans models.

Cambria Biosciences, based in Woburn, Mass., will also take part in the collaboration to carry high-throughput screening of several compound libraries.

The amount of the funding was not disclosed.


Note to Subscribers:
Cell-Based Assay News will not publish on Aug. 22. The next issue of the newsletter will appear on Aug. 29.
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.